Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details) $ in Millions	Mar. 31, 2022 USD ($)
Sanofi Collaboration Agreement, Immuno-oncology
Disaggregation of Revenue [Line Items]
Remaining performance obligation	$ 532.8

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant